Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
PFO repair may increase odds of postoperative stroke, shows no clear benefit: Study

PFO repair may increase odds of postoperative stroke, shows no clear benefit: Study

Gersak develops Convergent Procedure for atrial fibrillation

Gersak develops Convergent Procedure for atrial fibrillation

Catheter ablation benefits atrial fibrillation patients younger than 45

Catheter ablation benefits atrial fibrillation patients younger than 45

FDA recommends dabigatran etexilate to prevent stroke in AF patients

FDA recommends dabigatran etexilate to prevent stroke in AF patients

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

New computerized catheter makes surgical treatment of atrial fibrillation faster, cheaper and more effective

New computerized catheter makes surgical treatment of atrial fibrillation faster, cheaper and more effective

Convergent Procedure for AF highlighted at EACTS 2010

Convergent Procedure for AF highlighted at EACTS 2010

FDA approves CorMatrix ECM for Pericardial Closure

FDA approves CorMatrix ECM for Pericardial Closure

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

AHRQ releases free evidence-based guides for eight health conditions

AHRQ releases free evidence-based guides for eight health conditions

XARELTO achieves net clinical benefit in treatment of patients with DVT

XARELTO achieves net clinical benefit in treatment of patients with DVT

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

ESC updates Clinical Practice Guidelines on devices for heart failure treatment

ESC updates Clinical Practice Guidelines on devices for heart failure treatment

ESC announces new Clinical Practice Guidelines on Atrial Fibrillation

ESC announces new Clinical Practice Guidelines on Atrial Fibrillation

ESC issues revised practice guidelines for management of AF

ESC issues revised practice guidelines for management of AF

DANPACE trial shows dual chamber pacing decreases atrial fibrillation in sick sinus syndrome

DANPACE trial shows dual chamber pacing decreases atrial fibrillation in sick sinus syndrome

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Get With The Guidelines can improve quality of stroke care

Get With The Guidelines can improve quality of stroke care

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Data monitoring committee recommends early termination following impressive results of AVERROES study

Data monitoring committee recommends early termination following impressive results of AVERROES study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.